Use of synthetic polypeptide in maintenance of stem cell stemness
By using the modified polypeptide H10, the problem of stem cell loss in in vitro passage is solved, the high-level expression of stem cell stem genes and the maintenance of proliferation ability of stem cells is achieved, and the stem maintenance time of stem cells is extended.
Patent Information
- Application Number
- PCT/CN2023/143149
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-24
- Filing Date
- 2023-12-29
- Publication Date
- 2024-11-28
AI Technical Summary
During the long-term in vitro passage of stem cells, the differentiation ability of mesenchymal stem cells is significantly reduced, resulting in loss of stemness, which in turn affects its application effect in cell therapy.
Using a specific synthetic polypeptide H10 with an amino acid sequence of Ac-Lys-Val-Arg-(D)Pro-Ile-Ser-Met-Ser-Thr-Leu, the first lysine was acetylated and the use of D type Proline modifies the fourth proline, which is used to maintain stemness of stem cells and promote the expression of OCT4, SOX2, KLF4 and NANOG genes.
H10 polypeptide can effectively maintain the stemness of stem cells, ensure that it expresses stem genes at a high level during multiple passages, prolongs the stemness maintenance time of stem cells, and significantly promotes the proliferation of stem cells.
Smart Images

Figure CN2023143149_28112024_PF_FP_ABST
Abstract
Description
Application of a synthetic peptide in maintaining stem cell stemness Technical Field
[0001] The present invention relates to the technical field of stem cell stemness research, and more specifically, to the application of a synthetic polypeptide in maintaining the stemness of stem cells. Background Art
[0002] Stem cells (SCs) are a type of undifferentiated, multipotent cell with the ability to self-replicate. They are relatively primitive cells that, under certain conditions, can differentiate into cells with multiple functions. Stem cells can be divided into embryonic stem cells and adult stem cells based on their developmental state, and into totipotent stem cells, pluripotent stem cells, and unipotent stem cells based on their differentiation potential.
[0003] The self-renewal and stemness maintenance of stem cells depend on the expression of stemness genes. Common stemness genes include OCT4, SOX2, KLF4, NANOG, c-Myc, etc. Therefore, the expression of stemness genes is also a marker for measuring the stemness of stem cells.
[0004] Mesenchymal stem cells (MSCs) are multipotent stem cells derived from the mesoderm, possessing a high degree of self-renewal and multidirectional differentiation potential. They are widely present in various tissues throughout the body. They can be cultured and expanded in vitro and, under specific conditions, differentiate into neurons, osteoblasts, chondrocytes, muscle cells, adipocytes, and other cells, making them ideal candidates for tissue regeneration and disease treatment. Given the scarcity of bone marrow donations and the extremely low proportion of MSCs in tissue cells, in vitro expansion is essential for the application of MSCs.
[0005] However, with long-term in vitro passage, many MSCs exhibit a significant decrease in their differentiation capacity, manifesting as abnormal morphology, reduced expression of specific surface antigens, decreased colony formation and proliferation, and reduced differentiation potential. Ultimately, MSCs lose the capacity required for tissue regeneration (i.e., stemness), leading to poor therapeutic efficacy. This has become a key issue hindering the clinical application of MSC-based cell therapy. Maintaining the stemness of mesenchymal stem cells after continuous passage is a pressing challenge in the field of cell therapy. Technical issues
[0006] The technical problem to be solved by the present invention is to overcome the above-mentioned problems existing in the prior art. First, an H10 peptide is provided.
[0007] A second object of the present invention is to provide a product containing an H10 peptide.
[0008] The third object of the present invention is to provide a use of H10 peptide. Technical Solutions
[0009] The purpose of the present invention is achieved through the following technical solutions:
[0010] An H10 peptide, the amino acid sequence of the H10 peptide is shown in SEQ ID NO: 1.
[0011] The amino acid sequence of the H10 peptide is as follows: Ac-Lys-Val-Arg-(D)Pro-Ile-Ser-Met-Ser-Thr-Leu, wherein the first lysine is acetylated (Ac) and the fourth position is D-proline.
[0012] Preferably, the H10 peptide is used to maintain the stemness of mesenchymal stem cells.
[0013] More preferably, the H10 peptide can maintain the stemness of mesenchymal stem cells after passage; the H10 peptide can maintain the stemness of mesenchymal stem cells after passage 15.
[0014] The present invention also provides the use of the H10 peptide for increasing the expression of stemness genes OCT4, SOX2, KLF4 and NANOG in mesenchymal stem cells. Beneficial effects
[0015] Compared with the prior art, the present invention has the following beneficial effects:
[0016] The present invention provides the use of a synthetic polypeptide for maintaining stem cell stemness, belonging to the field of stem cell technology. Experiments demonstrate that the H10 polypeptide can effectively promote the expression of the OCT4, SOX2, KLF4, and NANOG genes in mesenchymal stem cells. Even after multiple passages, high levels of stemness genes can still be expressed, demonstrating that the H10 polypeptide can effectively maintain the stemness of mesenchymal stem cells. BRIEF DESCRIPTION OF THE DRAWINGS
[0017] FIG1 shows the effects of different concentrations of H10 peptide on the proliferation of mesenchymal stem cells;
[0018] FIG2 shows the effect of H10 peptide on the expression of stem cell stemness-related genes.
[0019] Figure 3 shows the effects of different concentrations of H10 peptide on the proliferation of mesenchymal stem cells;
[0020] FIG4 shows the effect of H10 peptide on the expression of stemness-related genes in mesenchymal stem cells. Best Mode for Carrying Out the Invention
[0021] The following is a further description of specific embodiments of the present invention. It should be noted that the description of these embodiments is intended to facilitate understanding of the present invention and does not constitute a limitation of the present invention. In addition, the technical features involved in the various embodiments of the present invention described below may be combined with each other as long as they do not conflict with each other.
[0022] Example 1 Design and synthesis of polypeptides
[0023] Stem cell factor (SCF) derivative peptides from different species (human, dog, rat, mouse, horse, and tree shrew) were designed, and their sequences are shown in Table 1.
[0024] Example 2 Extraction and primary culture of rat bone marrow mesenchymal stem cells
[0025] SD rats were killed by cervical dislocation. After disinfection with 70% ethanol, the femoral skin was cut open, the muscles on the femur were separated, and the femur was cut at both ends of the joint and placed in a sterile PBS dish. The muscles were removed and the femur was rinsed three times with sterile PBS. The femur was cut in the middle, and the bone marrow cavity was repeatedly flushed with low-glucose DMEM culture medium (containing 1 mL / L heparin) using a syringe to flush out the bone marrow. The bone marrow fluid was repeatedly flushed with a syringe and passed through a No. 7 and No. 4 needles to prepare a single-cell suspension.
[0026] The single cell suspension was centrifuged (1500 rpm) and the supernatant was discarded. DMEM-F12 complete medium containing 10% FBS was added and the cells were dispersed by pipetting. The cells were counted and counted as 10 7 The cells were seeded at a density of 10000 cells / mL in a culture flask and cultured in a 37°C, 5% CO2 incubator. The culture medium was replaced every 3 days to remove non-adherent hematopoietic cells. The cells were passaged until they were 80%-90% full. After trypsin digestion, the cells were transferred to a centrifuge tube and centrifuged at 1500 r / min for 10 min. The supernatant was removed and the cells were resuspended in the complete culture medium of mesenchymal stem cells. The cells were cultured at a density of 10000 cells / cm 2 The cells were seeded at a density of 100 μg / mL. Sufficient complete culture medium for mesenchymal stem cells was added for culture.
[0027] Example 3 Activity selection of polypeptides
[0028] The activity of candidate peptides was screened using the expression level of the mesenchymal stem cell stemness gene OCT4. The steps are as follows:
[0029] 1. RNA Extraction
[0030] (1) Rat bone marrow mesenchymal stem cells at passage 5 (P5), passage 10 (P10), and passage 15 (P15) were seeded into 6-well plates. After the cells adhered to the plate, control and experimental groups were set up. The control group was treated with culture medium for 96 hours, and the experimental group was treated with 50 μg / ml H10 peptide for 96 hours.
[0031] (2) After the treatment, remove the culture medium and add 1 ml of Trizol to treat the cells. Use a pipette to repeatedly blow the cells. After standing for 5 minutes, transfer the cells to an enzyme-free EP tube.
[0032] (3) Add 200 μl of chloroform, shake and mix, and let it stand at room temperature for 10 min;
[0033] (4) Place the EP tube in a centrifuge at 12,000 rpm and 4°C for 10 minutes.
[0034] (5) After centrifugation, aspirate the supernatant into a new EP tube, add 500 μl of pre-cooled isopropanol, mix well, and place on ice for 10 minutes;
[0035] (6) Place the EP tube in a centrifuge at 12,000 rpm and 4°C for 10 minutes.
[0036] (7) Remove the supernatant, retain the white precipitate, and add 1 ml of 75% ethanol solution to mix the precipitate;
[0037] (8) Place the EP in a centrifuge at 8000 rpm, 4°C, and centrifuge for 5 minutes;
[0038] (9) After centrifugation, carefully remove the supernatant and let it stand at room temperature for 10 minutes. After the RNA is dry, add 25 μl of DEPC water to dissolve the RNA.
[0039] 2. Reverse Transcription
[0040] (1) Removal of DNA from the genome
[0041] RNase-free DNase I (Promega) was used to prepare the reaction solution according to the system in Table 2. The digestion was carried out at 37°C for 30 min and then inactivated at 65°C for 10 min.
[0042] (2) Reverse transcription reaction
[0043] The reaction solution was prepared according to the reaction system in Table 3, and reverse transcription was performed. The reaction conditions were: incubation at 30°C for 10 min, incubation at 42°C for 60 min, and incubation at 85°C for 10 min.
[0044] 3. Fluorescence quantitative PCR
[0045] The primers listed in Table 4 were used to amplify the OCT4 gene, and the glyceraldehyde-3-phosphate dehydrogenase (GAPDH) gene was used as an internal reference.
[0046] The reaction system is shown in Table 5.
[0047] Fluorescence quantitative PCR reaction conditions: pre-denaturation at 95°C for 200 s; followed by 95°C for 20 s, 55°C for 20 s, and 72°C for 20 s as one cycle, for a total of 40 cycles.
[0048] 4. Calculate the relative expression of mRNA.
[0049] The 2-△△ ct method was used to calculate and analyze the relative expression level of the OCT4 gene in each reaction sample.
[0050] Results: As shown in Figure 1, compared with the saline control, most of the designed peptides were able to promote the expression of the stem cell gene OCT4, among which Peptide H had the strongest promoting effect. Therefore, Peptide H was selected for subsequent studies.
[0051] Example 4 Modification of Peptide H and Synthesis of Comparative Peptides
[0052] Peptide H was modified to improve its stability by acetylation (Ac) at the first amino acid (Lys) and substitution of the fourth amino acid (Pro) with D-proline (Pro). 50 mg of this modified peptide was synthesized using solid-phase synthesis with a purity >95%. The resulting peptide sequence is: Ac-Lys-Val-Arg-(D)Pro-Ile-Ser-Met-Ser-Thr-Leu.
[0053] Comparative Example 1
[0054] 50 mg of the peptide from Comparative Example 1 was synthesized using solid-phase synthesis with a purity of >95%. The sequence of the synthesized peptide from Comparative Example 1 was: Lys-Val-Arg-Pro-Ile-Ser-Met-Ser-Thr-Leu, i.e., the first amino acid (Lys) was not acetylated (Ac), and the fourth amino acid (Pro) was not a D-amino acid.
[0055] Comparative Example 2
[0056] 50 mg of the peptide of Comparative Example 2 was synthesized by solid-phase synthesis with a purity of >95%. The sequence of the synthesized peptide of Comparative Example 2 was: Ac-Lys-Val-Arg-Pro-Ile-Ser-Met-Ser-Thr-Leu, i.e., the first amino acid (Lys) was acetylated (Ac), but the fourth amino acid (Pro) was not a D-amino acid.
[0057] Comparative Example 3
[0058] 50 mg of the peptide from Comparative Example 3 was synthesized using solid-phase synthesis with a purity of >95%. The sequence of the synthesized peptide from Comparative Example 3 was: Lys-Val-Arg-(D)Pro-Ile-Ser-Met-Ser-Thr-Leu, i.e., the first amino acid (Lys) was not acetylated (Ac), but the fourth amino acid (Pro) was a D-amino acid.
[0059] Example 5 Stability Test
[0060] The HPLC method was used to determine the purity of the samples prepared in Example 4 and Comparative Examples 1, 2 and 3 after different storage times to evaluate the stability of the samples.
[0061] Establishment of HPLC method: The following chromatographic system and chromatographic conditions were used for HPLC detection of samples.
[0062] Instrument: Thermo U3000 HPLC system, equipped with LPG-3400SD pump, WPS-3000 autosampler, VWD-3100 UV detector, and TCC-3000 column oven;
[0063] Column: Synergi 4μm Hydro-RP 80Å (4.6*150mm, 4μm);
[0064] Mobile phase: A, 0.1% Trifluoroacetic in 100% water;
[0065] B, 0.1% Trifluoroacetic in 100% acetonitrile;
[0066] Column temperature: 45°C;
[0067] Detection wavelength: 220 nm;
[0068] Flow rate: 1 mL / min;
[0069] Injection volume: 15 μL;
[0070] The elution program is shown in Table 6.
[0071] Weigh 5 mg of each sample and aliquot each into six EP tubes. Store airtight and protected from light in a stabilization chamber at 45°C and 75% relative humidity. Samples were collected and analyzed after 0, 1, 5, 10, 20, and 30 days. Purity was determined using the previously established HPLC method, with area normalization used to determine the purity of the main peak.
[0072] Each sample was injected twice, and the average of the two measurements was taken as the final result.
[0073] The sample stability results are shown in Figure 2. It can be seen that the main peak purity of the sample prepared in Example 4 did not decrease significantly after 30 days of storage, while the main peak purity of the samples prepared in Comparative Examples 1, 2, and 3 all decreased significantly, among which the main peak purity of the sample prepared in Comparative Example 3 decreased most significantly. The results show that the modification performed in Example 4 can significantly improve the stability of the Peptide H polypeptide.
[0074] In summary, the modified peptide of Example 4 was finally selected for subsequent studies and renamed as H10 peptide.
[0075] Example 6 Effect of H10 peptide on the proliferation of mesenchymal stem cells
[0076] The experimental process is as follows:
[0077] (1) Rat bone marrow mesenchymal stem cells at passage 3 (P3) were seeded into a 96-well plate, with 1000 cells per well and 100 μl per well, and one blank well without cells was set up;
[0078] (2) After the cells adhered, they were treated with 0 (medium control), 10, 20, 50, and 100 μg / ml H10 peptide, respectively, with three replicate wells set up for each group;
[0079] (3) Place the cell culture plate in a cell culture incubator and continue culturing for 72 hours;
[0080] (4) After the incubation period, the culture medium was removed and 10 μl of CCK-8 was added to each well in the dark. After incubation for 3 h, the absorbance of each group was measured at 450 nm.
[0081] Results: The proliferation of mesenchymal stem cells in each group is shown in Figure 3. It can be seen that different concentrations of H10 peptide can promote the proliferation of mesenchymal stem cells. Among them, the promoting effect of 20-100 μg / ml has statistical significance (P < 0.01), indicating that H10 peptide has a significant effect on the proliferation of mesenchymal stem cells.
[0082] Example 7 Regulation of stemness-related genes of mesenchymal stem cells by H10 polypeptide
[0083] 1. RNA Extraction
[0084] Same as Example 3.
[0085] 2. Reverse Transcription
[0086] Same as Example 3.
[0087] 3. Fluorescence quantitative PCR
[0088] The primers in Table 7 were used to amplify the OCT4, SOX2, NANOG, and KLF4 genes, and the glyceraldehyde-3-phosphate dehydrogenase (GAPDH) gene was used as an internal reference.
[0089] The reaction system is shown in Table 5.
[0090] Fluorescence quantitative PCR reaction conditions: pre-denaturation at 95°C for 200 s; followed by 95°C for 20 s, 55°C for 20 s, and 72°C for 20 s as one cycle, for a total of 40 cycles.
[0091] 4. Calculate the relative expression of mRNA.
[0092] The 2-△△ ct method was used to calculate and analyze the relative expression levels of OCT4, SOX2, NANOG and KLF4 genes in each reaction sample.
[0093] Results: The experimental results are shown in Figure 4. As can be seen, the relative expression levels of the stemness-related genes OCT4, SOX2, NANOG, and KLF4 in rat mesenchymal stem cells (experimental group) treated with 50 μg / ml H10 peptide were significantly higher than those in the control group at passages 5, 10, and 15, with statistical significance (P < 0.01). These results indicate that treatment of rat bone marrow mesenchymal stem cells with H10 peptide resulted in high expression of stemness-related genes, and that these genes remained highly expressed after continuous passage. Therefore, H10 peptide can effectively maintain the stemness of continuously passaged mesenchymal stem cells.
[0094] The embodiments of the present invention are described in detail above, but the present invention is not limited to the described embodiments. It is apparent to those skilled in the art that various changes, modifications, substitutions, and variations of these embodiments may be made without departing from the principles and spirit of the present invention, and the changes still fall within the scope of protection of the present invention.
Claims
1. An H10 peptide, characterized in that The amino acid sequence of the H10 peptide is shown in SEQ ID NO: 1, wherein the first amino acid is acetylated and the fourth amino acid is D-proline.
2. Use of the H10 peptide according to claim 1 in promoting the proliferation of mesenchymal stem cells.
3. The use according to claim 2, characterized in that: The concentration of H10 peptide was 20-100 μg / ml.
4. Use of the H10 peptide according to claim 1 in maintaining the stemness of mesenchymal stem cells.
5. The use according to claim 4, characterized in that: H10 peptide can maintain the stemness of mesenchymal stem cells during passage.
6. The use according to claim 5, characterized in that: H10 peptide can maintain the stemness of mesenchymal stem cells after 15 generations.
7. Use of the H10 peptide according to claim 1 to increase the expression of stemness genes OCT4, SOX2, KLF4 and NANOG in mesenchymal stem cells.
8. The use according to any one of claims 4 to 6, characterized in that: The H10 peptide concentration was 50 μg / ml.
9. The use according to claim 7, characterized in that: The H10 peptide concentration was 50 μg / ml.
Citation Information
Patent Citations
Culture medium supplementing composition, stem cell culture medium and preparation method of stem cell culture medium
CN112608884A
Application of Nigroain-E1 polypeptide in maintaining dryness of adipose-derived stem cells
CN113717935A
Application of synthetic polypeptide in maintaining dryness of stem cells
CN116836227A
Cosmetic composition biomimetically designed from extracellular matrix for promoting the stemness of adipose-derived stem cell
KR1020120058866A
Composition for promoting production of stem cell-derived exosomes and increasing stemness
US20220195384A1
Cited By
Fusion type polypeptide for improving activity of umbilical cord mesenchymal stem cells and application of fusion type polypeptide
CN120383684A
